Clinical trial Recruiting at 3 sites Observational Ages 18 and up

Using flecainide to treat frequent premature ventricular contractions and related heart issues

Official title: UNIFLECA Study: Prospective Cohort Study on Flecainide's Impact on Persistent High Premature Ventricular Contraction Burden and PVC-Induced Cardiomyopathy

Run by University of Athens · NCT06949748 · Data updated 2026-11-12

This study is testing if the heart medication flecainide can help adults with frequent heartbeats and related heart issues who can't or don't want to have a procedure called catheter ablation.

More Cardiomyopathies trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment300 (estimated)
SponsorUniversity of Athens
Academic / other
Locations6 sites (Pátrai, Achaia and 5 other locations)
StatusRecruiting
StartedApril 26, 2024
Main results expectedJuly 1, 2027
Study endsDecember 1, 2027
Registry record updatedJuly 2, 2025
Trial IDNCT06949748 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with frequent idiopathic PVCs and structurally normal hearts who have declined or are ineligible for catheter ablation.

Probably not a fit

Patients with structural heart disease, ischemic heart disease, or significant ventricular arrhythmias are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The UNIFLECA study is an observational cohort that evaluates the efficacy, safety, and tolerability of flecainide in adults experiencing frequent idiopathic premature ventricular contractions (PVCs) and suspected PVC-induced cardiomyopathy. Participants undergo thorough cardiac evaluations, including echocardiography and cardiac MRI, to confirm the absence of structural heart disease. Flecainide is administered as monotherapy, starting at a dose of 100 mg/day and potentially increasing to 200 mg/day based on clinical response and ECG findings. This study specifically targets patients who are ineligible or unwilling to undergo catheter ablation.

Why it matters

Potential benefit: If successful, this study could provide an effective treatment option for patients suffering from PVC-induced cardiomyopathy, potentially reversing left ventricular dysfunction.

How similar studies have gone: While the use of flecainide for PVCs is established, this specific approach in a cohort with PVC-induced cardiomyopathy is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Frequent idiopathic PVCs (burden \>5% on multiple 24-hour Holter ECG recordings)
* Normal cardiac structure and function on echocardiography
* No late gadolinium enhancement or myocardial scar on cardiac MRI
* Normal coronary angiography (excluding ischemic cardiomyopathy)
* Normal serum electrolytes and renal function
* Willingness to comply with follow-up schedule and drug titration

Exclusion Criteria:

* Structural heart disease
* Ischemic heart disease (confirmed by angiography)
* History of sustained ventricular arrhythmias
* Left ventricular ejection fraction (LVEF) \<40% at baseline
* Brugada syndrome, long QT syndrome, or other channelopathies
* Contraindications to class IC agents
* Use of concurrent antiarrhythmics or proarrhythmic drugs

Where it's running

  • Cardiology Clinic, University Hospital of Patras
    Pátrai, Achaia, Greece
    Recruiting
  • 1st Cardiology Clinic, National and Kapodistrian University of Athens
    Athens, Attica, Greece
    Recruiting
  • Cardilogy Clinic, University of Crete
    Heraklion, Greece
    Recruiting
  • 2nd Cardiology Clinic, University of Ioannina
    Ioannina, Greece
    Active not recruiting
  • 2nd Cardiology Clinic, Aristotle University of Thessaloniki
    Thessaloniki, Greece
    Active not recruiting
  • 3rd Cardiology Clinic, Aristotle University of Thessaloniki
    Thessaloniki, Greece
    Active not recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Catheter ablation vs. anti-arrhythmic drugs for PVCs

    This study tests whether catheter ablation or anti-arrhythmic medications are better at reducing PVC symptoms and improving quality of life for adults with a normal heart function.

    Recruiting Western Sydney Local Health District · Westmead, New South Wales · NCT07445334

  • Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS

    Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.

    Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07912086

  • Severe Complications During VT/PVC Ablation

    This study looks at real-world cases to see what severe complications occur during VT or PVC ablations and how patients are managed afterward.

    Recruiting at 25 sites University Hospital, Basel, Switzerland · Chicago, Illinois and 24 other locations · NCT07777744

  • Liver and Coagulation Markers in ATTR Cardiac Amyloidosis

    This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.

    Recruiting University of Messina · Messina, Sicily · NCT07766135

  • Stepwise withdrawal of ARNI and SGLT2i in HF with normalized ejection fraction

    This trial tests whether gradually stopping ARNI and SGLT2i is safe for people whose heart function has recovered after fixing a reversible heart‑disease cause.

    Recruiting Phase 4 Keimyung University Dongsan Medical Center · Daegu, Daegu and 4 other locations · NCT07631156

  • RHYthm and Myocardial Function Relationship in Heart Disease

    This study tests how heart rhythm patterns relate to heart muscle function in adults with arrhythmias or cardiomyopathy.

    Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07491237

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.